Shares of Moderna, Inc. ($MRNA), among the frontrunners in mRNA vaccine technology, fell on Tuesday, bucking the broader market strength. The weakness came after Bloomberg reported, citing a person ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Japan’s Takeda recently withdrew its US Food & Drug Administration (FDA) approval application for another vaccine, Qdenga ...

Four men have been diagnosed with Trichophyton mentagrophytes type VII since spring. Also, whooping cough cases — almost 20,000 — are almost back to pre-pandemic levels; California and Washington ...

Vaccine advisers to the Food and Drug Administration (FDA) today recommended switching the SARS-CoV-2 ... longer manufacturing timelines—about 6 months, which is similar to flu vaccines—than mRNA ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The 25,000-subject study is testing a nucleoside-modified mRNA (modRNA), quadrivalent vaccine that is targeted against four strains of the flu virus that the World Health Organization (WHO ...

Donald Trump’s pledge to let Robert F. Kennedy Jr. “go wild on health” has put three issues on the agenda in the final days ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Low-wage health care workers struggle with post-traumatic stress from the covid pandemic and living at home alone as you age can be bad for your physical health. Oct. 17 This week on the ...

Editorial writers discuss these public health issues.